**Textbooks**

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Author(s)</th>
<th>Edition</th>
<th>Publisher, Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1983</td>
<td>Drugs - Applied Pharmacology for Pharmacists and Pharmacy Technicians (in German)</td>
<td>H. Derendorf</td>
<td></td>
<td>Deutscher Apotheker-Verlag, Stuttgart, Germany</td>
</tr>
<tr>
<td>1987</td>
<td>Pharmacokinetics - Introduction into Theory and Practice&quot; (in German)</td>
<td>H. Derendorf and E.R. Garrett</td>
<td></td>
<td>Deutscher Apotheker -Verlag, Stuttgart, Germany</td>
</tr>
<tr>
<td>1988</td>
<td>Drugs - Applied Pharmacology for Pharmacists and Pharmacy Technicians (in German), 4th edition</td>
<td>H. Derendorf</td>
<td>4th</td>
<td>Deutscher Apotheker Verlag, Stuttgart, Germany</td>
</tr>
<tr>
<td>1994</td>
<td>Drugs - Applied Pharmacology for Pharmacists and Pharmacy Technicians (in German), 5th edition</td>
<td>H. Derendorf</td>
<td>5th</td>
<td>Deutscher Apotheker Verlag, Stuttgart, Germany</td>
</tr>
<tr>
<td>1995</td>
<td>Drug Actions (in English)</td>
<td>E. Mutschler and H. Derendorf</td>
<td></td>
<td>Deutscher Apotheker Verlag, Stuttgart, Germany</td>
</tr>
<tr>
<td>1995</td>
<td>Handbook of Pharmacokinetic-Pharmacodynamic Correlations (in English)</td>
<td>H. Derendorf and G. Hochhaus</td>
<td></td>
<td>CRC Press, Boca Raton, Florida</td>
</tr>
<tr>
<td>1995</td>
<td>Pharmaceutical Care (in German)</td>
<td>J. Framm, M. Schäfer, H. Derendorf</td>
<td></td>
<td>Deutscher Apotheker Verlag, Stuttgart, Germany</td>
</tr>
</tbody>
</table>


2003  H. Derendorf, M. Schulz, R. Wemhöner Pharmacology for Pharmacists and Pharmacy Technicians (in German), 7th edition, 304 p., Deutscher Apotheker Verlag, Stuttgart, Germany


List of Publications

1. P. Rohdewald, H. Derendorf, C.E. Elger, O. Knoll
   Quantification of the attenuation of pain sensation through evoked potentials after the application of mild analgesics.
   Z. EEG-EMG 11, 199-204 (1980).

2. H. Derendorf
   Electroencephalography in drug research.

3. H. Derendorf, P. Rohdewald
   Pharmaceutical availability of analgesic derivatives of salicylic acid.

4. H. Derendorf, P. Rohdewald
   Pharmaceutical availability of analgesic derivatives of pyrazolone.

5. H. Derendorf, P. Rohdewald
   Measurement of analgesic action by subjective and objective parameters.

6. H. Derendorf, P. Rohdewald
   Pharmaceutical availability of analgesic derivatives of p-aminophenol in tablets.

7. P. Rohdewald, H. Derendorf, C.E. Elger, O. Knoll
   Evoked potentials as objective parameters for the analgesic response of weak analgesics.

   Changes in cortical evoked potentials as correlates of the efficacy of weak analgesics.
9. H. Derendorf, G. Drehsen, P. Rohdewald
Cortical evoked potentials and saliva levels as basis for the comparison of pure analgesic to analgesic combinations.

10. H. Derendorf
Phencyclidine - angel dust or devil's drug?

11. H. Derendorf, E.R. Garrett
HPLC-Assay of methadone, phencyclidine and metabolites by post-column ion-pair extraction and "on-line" fluorescence detection of the counter-ion with applications.

12. P. Rohdewald, G. Drehsen, E. Milsmann, H. Derendorf
Relationship between saliva levels of metamizol metabolites, bioavailability and analgesic efficacy.

13. H. Derendorf, G. Drehsen, P. Rohdewald
In vivo- in vitro- correlations of salicylate saliva levels and continuous flow cell dissolution rates.
Int. J. Pharm. 15, 167-175 (1983).

Electrochemical chromatographic determination of morphine - antagonists in biological fluids with applications.

15. H. Derendorf, G. Drehsen, P. Rohdewald
Antipyrine - new light on an old drug.

16. P. Rohdewald, G. Drehsen, H. Derendorf
Phenazone, the underestimated analgesic.

17. G. Drehsen, H. Derendorf, P. Rohdewald
Pain relief- but when?
Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma.

Kinetics of methylprednisolone and its hemisuccinate ester.

20. R.L. Yost, H. Derendorf
Rapid chromatographic determination of cefotaxime and its metabolite in biological fluids.

Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate.

22. E.R. Garrett, H. Derendorf, A. Mattha
Pharmacokinetics of morphine and its surrogates VI: HPLC-Analyses and pharmacokinetics of methadone and its derived metabolites in dogs.

Pharmacokinetics of triamcinolone acetonide and its phosphate ester.

The attenuation of experimental pain by pyrazolones.
In "100 years pyrazolones", ed. by K. Brune and R. Lanz, Urban & Schwarzenberg, pg. 61-67 (1985).

25. H. Möllmann, J. Barth, K.M. Müller, P. Rohdewald, A. Grüner, H. Derendorf
Pulmonary complications in intensive care patients-therapeutic approaches for the treatment of ARDS
HPLC determination of glucocorticoid alcohols, their
phosphates and hydrocortisone in aqueous solutions and
biological fluids.

27. H. Derendorf, G. Mullersman, J. Barth, A. Grüner, H.
Möllmann
Pharmacokinetics of diclofenac sodium after
intramuscular administration in combination with
triamcinolone acetate.

28. G. Mullersman, H. Derendorf
Ranitidine - rapid analysis in biological fluids and
determination of erythrocyte partitioning.

29. G. Mullersman, V.P. Gotz, W.L. Russell, H. Derendorf
Lack of clinically significant in vitro and in vivo
interactions between ranitidine and sucralfate.

30. R.L. Yost, H. Derendorf
Pharmacokinetics of cefotaxime and its metabolite in
normal and morbidly obese patients.
Ther. Drug Monitor. 8, 189-194 (1986).

31. H. Derendorf, H. Möllmann, A. Grüner, D. Haack, G.
Gyselby
Pharmacokinetics and pharmacodynamics of
glucocorticoid suspensions after intraarticular
administration.

32. H. Möllmann, J. Rehder, P. Rohdewald, B.E. Braun, J.
Barth, H. Derendorf, B. Holtmann, A. Grüner
Exogenous and endogenous glucocorticoid plasma level
after intramuscular administration of diclofenac and
triamcinolone diacetate
Comparison of the kinetics and dynamics of intraarticular glucocorticoid suspensions.
Akt. Rheumatol. 11, 55-60 (1986).

34. H. Derendorf, M. Kaltenbach
Coulometric high-performance liquid chromatographic-analysis morphine in biological fluids.

35. P. Rohdewald, H. Möllmann, J. Barth, J. Rehder, H. Derendorf
Pharmacokinetics of dexamethasone and its phosphate ester.

36. S.A. Stout, H. Derendorf
Local treatment of respiratory infections with antibiotics.

37. H. Derendorf
Erythrocyte - binding of cepholosporins.

38. P. Rohdewald, J. Rehder, H. Möllmann, J. Barth, H. Derendorf
Pharmacokinetics and pharmacodynamics of prednisolone after extremely high doses of prednisolone hemisuccinate.

39. G. Mullersman, S. Toufflin, H. Derendorf
HPLC analysis of buprenorphine in plasma and urine using coulometric detection.

40. S.A. Stout, C.M. Riley, H. Derendorf
The correlation between the pharmacokinetics of melphalan and the pharmacodynamic response of neuroblastoma cells treated in vitro.
41. H. Derendorf
Pharmacokinetic evaluation of cefotaxime in normal and obese subjects.

42. H. Möllmann, P. Rohdewald, J. Barth, H. Derendorf
Effect of high doses of glucocorticoids on the kinetics of human white blood cells in vivo.

43. G. Mullersman, H. Derendorf, M.E. Brewster, K.S. Estes, N. Bodor
HPLC-Assay of a CNS directed estradiol chemical delivery system and its application after intravenous administration to rats.

44. H. Möllmann, P. Rohdewald, J. Barth, H. Derendorf, C. Möllmann, M. Verho.
Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses.

45. L.A. Berglund, H. Derendorf, J.W. Simpkins
Desensitation of brain opiate receptor mechanisms by gonadal steroid treatments that stimulate luteinizing hormone secretion.

High-performance liquid chromatographic determination of conjugated estrogens in tablets.

47. J. Limberg, H. Derendorf
Pharmacy education in the U.S.A.

48. E.W. Schmidt, H.W. Möllmann, B.E. Braun, J. Barth, H. Derendorf
Circadian theophylline levels after single and multiple administration of a sustained released dosage form.

50. H. Derendorf

51. H. Möllmann, J. Barth, D. Schött, W.T. Ulmer, H. Derendorf, G. Hochhaus

52. M.E. Brewster, T. Loftsson, K.E. Estes, G. Mullersman, H. Derendorf, N. Bodor

53. H. Möllmann, P. Rohdewald, J. Barth, M. Verho, H. Derendorf

54. H. Derendorf, H. Möllmann, P. Rohdewald, D. Strohband, J. Barth, G. Hochhaus

55. J. Barth, H.W. Möllmann, H. Derendorf, G. Hochhaus

56. J. Barth, A. Möllmann, G. Hochhaus, H. Derendorf, H.W. Möllmann
57. E.W. Schmidt, H. Derendorf, B. Rasche, H.W. Möllmann
Clinical and pharmacokinetic evaluation for the
replacement therapy of $\alpha_1$-protease-inhibitor in
patients with congenital $\alpha_1$-protease-inhibitor
deficiency and lung emphysema.

58. H.G. Schaefer, D. Harrison, M.P. Hocking, J. Limberg,
H. Derendorf
Effect of truncal vagotomy and partial gastrectomy on
the pharmacokinetics of propranolol enantiomers in
dogs.

59. H. Schreier, G. Hochhaus, R.J. Prankerd, H. Derendorf,
M.E. Brewster, R.A. Baughman
Pharmaceutical Biotechnology: A new graduate course at
the University of Florida College of Pharmacy.

60. J. Limberg, M. LeBel, H. Derendorf
Evaluation of free tissue concentrations of fleroxacin
after oral administration.

61. E. Brunt, J. Limberg, H. Derendorf
High performance liquid chromatographic-assay and
erthrocyte partitioning of fleroxacin, a new
fluoroquinolone antibiotic.

62. H. Derendorf, H. Möllmann, J. Barth
Comparative pharmacokinetic evaluation of
glucocorticoids after intraarticular administration.

Lopez, H. Derendorf
Simultaneous HPLC-assay of propranolol, diltiazem and
diltiazem-metabolites in human plasma with
application.
64. P. Adland-Davenport, M.P. Brown, J.D. Robinson, H. Derendorf
Pharmacokinetics of amikacin in critically ill neonatal foals treated for presumed or confirmed sepsis.

65. H. Derendorf, H. Möllmann, G. Voortman, F.A. van den Ouweland, L.B.A. van de Putte, G. Gevers, J. Dequeker, E. van Vliet-Daskalopoulou
Pharmacokinetics of rimexolone after intra-articular administration.

A redox-based system that enhances delivery of estradiol to the brain: Pharmacokinetic evaluation in the dog.

Simultaneous determination of propranolol and 4-hydroxypropranolol enantiomers after chiral derivatization using reversed phase high-performance liquid chromatography.

68. J. Limberg, D. Harrison, M.P. Hocking, H. Derendorf
Theophylline absorption and gastric emptying after partial gastrectomy in dogs.

69. M. Kaltenbach, S.H. Curry, H. Derendorf
Extent of drug absorption at the time of peak plasma concentration in an open one-compartment body model with first-order absorption.

70. K. Dietzel, K.S. Estes, M.E. Brewster, N.S. Bodor, H. Derendorf
The use of hydroxypropyl-β-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs.


78. H. Derendorf, H. Möllmann, M. Krieg, S. Tunn, C. Möllmann, J. Barth, H.J. Röthig
Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers.

79. B. Wichert, H. Schreier, H. Derendorf
Sensitive HPLC-assay for the determination of amikacin in human plasma.

80. C.D. Page, M. Mautino, H. Derendorf, W. Mechlinski
Multiple-dose pharmacokinetics of ketoconazole administered orally to gopher tortoises (Gopherus polyphemus).

81. T. Loftsson, M.E. Brewster, H. Derendorf, N. Bodor
2-Hydroxypropyl-β-cyclodextrin: Properties and usage in pharmaceutical formulations.

82. C.D. Page, M. Mautino, H. Derendorf, J.P. Anhalt
Comparative pharmacokinetics of trimethoprim-sulfamethoxazole administered intravenously and orally to captive elephants.

83. K.H. Rand, K. Gibbs, H. Derendorf, J. Graham-Pole
Pharmacokinetics of intravenous immunoglobulin in bone marrow transplant patients.

84. K.S. Estes, P. Dewland, M.E. Brewster, H. Derendorf, N. Bodor
A redox-based chemical delivery system (CDS) applied to estradiol.

85. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth
A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-isonicotinate in biological fluids.
86. M.A. Longer, H.G. Schaefer, H. Derendorf
Fundamentals of assessing bioequivalence studies.

Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.

88. H. Schreier, K.J. McNicol, M. Ausborn, D.M. Soucy, H. Derendorf, A.A. Stecenko, R.J. Gonzalez-Rothi
Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep.

89. S. Tunn, H. Möllmann, J. Barth, H. Derendorf, M. Krieg
Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration.

90. G. Hochhaus, R. Hochhaus, G. Werber, H. Derendorf, H. Möllmann
A selective HPLC/RIA for dexamethasone and its prodrug dexamethasone-21-sulphobenzoate sodium in biological fluids

91. H. Möllmann, H. Derendorf, J. Barth, C. Möllmann, S. Tunn, M. Krieg
Bioavailability of hydrocortisone after rectal administration of hydrocortisone acetate foam.

92. H. Derendorf
Choice of appropriate pharmacokinetic-pharmacodynamic models for predicting drug effects.

93. J. Barth, M. Damoiseaux, H. Möllmann, K.H. Brandis, G. Hochhaus, H. Derendorf
Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration.
94. S. Mohammed, M. Butschkau, H. Derendorf
A reversed phase liquid chromatographic method for the
determination of codeine in biological fluids with
application.

95. H. Derendorf, G. Hochhaus, H. Möllmann, J. Barth, M.
Krieg, S. Tunn, C. Möllmann
Receptor-based pharmacokinetic-pharmacodynamic
analysis of corticosteroids.

96. T. Wagner, J. Barth, A. Tromm, C. Bigalke, S. Tunn, M.
Krieg, H. Derendorf, H. Möllmann, B. May, G. Hochhaus
Bioavailability of hydrocortisone after single and
multiple dosing of hydrocortisone acetate foam in
patients with chronic distal inflammatory bowel
disease and healthy controls

97. S.S. Mohammed, M. Christopher, P. Mehta, A. Kedar, S.
Gross, H. Derendorf
Increased erythrocyte and protein binding of codeine
in patients with sickle cell disease

98. S.S. Mohammed, M. Ayass, P. Mehta, A. Kedar, S. Gross,
H. Derendorf
Codeine disposition in sickle cell patients compared
with healthy volunteers

99. J. Barth, G. Hochhaus, H. Derendorf, K.H. Lehr, T.
Hoehler, H. Möllmann
Prednicarbarte after different forms of administration:
plasma levels of drug and metabolites and effects on
endogenous cortisol levels in humans

100. J. Barth, K.H. Lehr, H. Derendorf, H. Möllmann, T.
Höhler, G. Hochhaus
Studies on the pharmacokinetics and metabolism of
prednicarbarte after cutaneous and oral administration.
Skin Pharmacol. 6, 179-186 (1993).
101. J. Barth, H. Möllmann, B. Armbruster, W. Flörke, G. Hochhaus, C. Möllmann, H. Derendorf
Analysis of shape, particle size, distribution and aggregation of the crystals of sodium cromoglycate and nedocromil sodium

Topical use of steroids in gastroenterology

Pharmacokinetic evaluation of two ibuprofen-codeine combinations

Development of an oral drug formulation for dichloroacetate and thiamine

105. H. Derendorf
Pharmacokinetic/pharmacodynamic consequences of space flight

Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep

107. A. Nolting, H. Derendorf
Pharmacokinetic Profile: Ceftazidime
108. R. Mies, J. van der Aa, C. Dixon, M. Kaltenbach, H. Derendorf, N. Gravenstein
Computer-modulated patient-controlled analgesia: Preliminary evaluation of a prototype

109. H. Derendorf
Pharmacodynamic aspects of systemic drug delivery

110. J. Barth, H. Möllmann, T. Wagner, G. Hochhaus, H. Derendorf
The validity of ‘equivalent doses’ in corticosteroid therapy - a comparison of the clinical pharmacokinetics and pharmacodynamics of prednisolone and methylprednisolone

Systemic delivery of the luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix (SB-75) via pulmonary instillation in the unanesthetized awake sheep

112. G. Hochhaus, R.J. Gonzalez-Rothi, A. Lukyanov, H. Derendorf, H. Schreier, T. Dalla Costa
Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats

113. H. Möllmann, S. Balbach, G. Hochhaus, J. Barth, H. Derendorf
Pharmacokinetic-pharmacodynamic correlations of corticosteroids

114. A. Nolting, H. Derendorf
Pharmacokinetic-pharmacodynamic modeling of antibiotics
115. G. Hochhaus, H. Derendorf
Dose optimization based on pharmacokinetic-pharmacodynamic modeling
In “Handbook of pharmacokinetic-pharmacodynamic correlations”, ed. by H. Derendorf and G. Hochhaus,

116. H. Derendorf, G. Hochhaus, S. Rohatagi, H. Möllmann, J. Barth, H. Sourgens, M. Erdmann
Pharmacokinetics of triamcinolone acetonide after intravenous, oral and inhaled administration

117. H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, H. Derendorf
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone

The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults

119. A. Nolting, H. Derendorf
Pharmacokinetic Profile: Ceftriaxone

120. S. Rohatagi, G. Hochhaus, H. Möllmann, J Barth and H. Derendorf
Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids

121. S. Rohatagi, G. Hochhaus, H. Möllmann, J. Barth, E. Galia, M. Erdmann, H. Sourgens, H. Derendorf
Pharmacokinetic/pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral and inhaled administration
122. S. Rohatagi, U. Täuber, K. Richter, H. Derendorf
Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone

123. S. Rohatagi, A. Bye, A. Mackie, H. Derendorf
Mathematical modeling of cortisol circadian rhythm and cortisol suppression

124. T. Dalla Costa, H. Derendorf
AUIC - a general target for the optimization of dosing regimens of antibiotics?

125. H. Möllmann, G. Hochhaus, S. Rohatagi, J. Barth, H. Derendorf, M. Krieg, H. Weisser, A. Möllmann
Pharmacokinetics and pharmacodynamics of cloprednol

126. H. Möllmann, M. Wagner, J. Barth, H. Derendorf, M. Schulz
Fluticasone, a new glucocorticoid for inhalation (in German)

127. A. Kovar, C. Schäfer, H. Derendorf
Pharmacokinetic Profile: Cefepime

Determination of free extracellular concentrations of piperacillin by microdialysis

129. A. Nolting, T. Dalla Costa, K.H. Rand, H. Derendorf
Pharmacokinetic-pharmacodynamic modelling of the antibiotic effect of piperacillin

130. H. Derendorf, T. Dalla Costa
Pharmacokinetics of piperacillin, tazobactam and its metabolite in renal impairment
131. H. Möllmann, J. Barth, G. Hochhaus, A. Möllmann, H. Derendorf, A. Tromm
Concepts of corticosteroid therapy of chronic inflammatory bowel disease: topical vs. systemic administration (in German)

132. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth, R. Hochhaus
Pharmacodynamic aspects of corticosteroid effects (in German)

133. H. Derendorf, H. Möllmann, G. Hochhaus, J. Barth
Kinetic/dynamic interrelationships as basis for rational therapy (in German)

134. H. Möllmann, G. Hochhaus, A. Tromm, P. Froehlich, A. Möllmann, M. Krieg, H. Weisser, H. Derendorf, J. Barth
Pharmacokinetics and pharmacodynamics of budesonide-pH-modified release capsules (in German)

Pulmonary targeting of liposomal triamcinolone acetonide phosphate

Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single i.v. dose in healthy volunteers
Arzneimittelforschung (Drug Research) 46, 615-621 (1996).
137. A. Suri, M. Kaltenbach, B. Grundy, H. Derendorf
Pharmacodynamic evaluation of codeine using tooth pulp
evoked potentials

138. S. Rohatagi, A. Bye, C. Falcoz, A. Mackie, B. Meibohm,
H. Möllmann, H. Derendorf
Dynamic modeling of cortisol reduction after inhaled
administration of fluticasone propionate

139. H. Möllmann, J. Barth, G. Hochhaus, A. Möllmann, H.
Derendorf, A. Tromm
Principles of topical versus systemic corticoid
treatment in inflammatory bowel disease
in ‘Glucocorticoid Therapy in Chronic Inflammatory
Bowel Disease’, ed. by H. Möllmann and B. May, Kluwer,
42-60 (1996).

140. G. Hochhaus, H. Derendorf, H. Möllmann, J. Barth, R.
Hochhaus
Pharmacodynamic aspects of glucocorticoid action
in ‘Glucocorticoid Therapy in Chronic Inflammatory
Bowel Disease’, ed. by H. Möllmann and B. May, Kluwer,

141. H. Derendorf, H. Möllmann, G. Hochhaus, J. Barth
Kinetic/dynamic interrelationships as basis for
rational therapy
in ‘Glucocorticoid Therapy in Chronic Inflammatory
Bowel Disease’, ed. by H. Möllmann and B. May, Kluwer,
80-98 (1996).

142. H. Möllmann, G. Hochhaus, A. Tromm, P. Froehlich, A.
Möllmann, M. Krieg, H. Weisser, H. Derendorf, J. Barth
Pharmacokinetics and pharmacodynamics of budesonide
pH-modified release capsules
in ‘Glucocorticoid Therapy in Chronic Inflammatory
Bowel Disease’, ed. by H. Möllmann and B. May, Kluwer,

143. A. Suri, B. Grundy, H. Derendorf
Pharmacokinetics and pharmacodynamics of enantiomers
of ibuprofen and flurbiprofen after oral
administration
144. H. Sourgens, H. Derendorf, H. Schifferer
Pharmacokinetic profile of cefaclor

145. A. Suri, K.S. Estes, G. Geisslinger, H. Derendorf
Pharmacokinetic-pharmacodynamic relationships for analgesics

Evaluation of a brain-targeting zidovudine chemical delivery system in dogs

147. A. Kovar, A. Nolting, H. Derendorf
Microdialysis for the determination of unbound tissue concentrations (in German)
PharmUZ 26, 17-23 (1997).

Comparison of plasma and free tissue levels of ceftriaxone in rats using microdialysis

Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis

Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-β-cyclodextrin-based formulation of carbamazepine in the dog: Comparison with commercially available tablets and suspensions

151. B. Meibohm, H. Derendorf
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modeling
152. T. Dalla Costa, A. Nolting, K. Rand, H. Derendorf
Pharmacokinetic-pharmacodynamic modeling of the in-vitro antiinfective effect of piperacillin-tazobactam combinations

153. H. Derendorf, H. Möllmann, G. Hochhaus, B. Meibohm, J. Barth
Clinical PK/PD modeling as a tool in drug development of corticosteroids

Dependency of cortisol suppression on the administration time of inhaled corticosteroids

155. S. Rohatagi, S. Kan, H. Derendorf
Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration
Pharmazie 52, 529-532 (1997).

156. G. Hochhaus, H. Möllmann, H. Derendorf, R.J. Gonzalez-Rothi
Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model

Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation

158. A. Kovar, H. Derendorf
Plasma and free tissue concentrations – significance for the evaluation of antibiotics (in German)
Krankenhauspharmazie 18, 564-567 (1997).

159. S. Rohatagi, J. Barth, H. Möllmann, G. Hochhaus, A. Soldner, C. Möllmann, H. Derendorf
Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral dosing
Relationship between plasma and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis

161. H. Derendorf
Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety

162. G. Hochhaus, P. Froehlich, R. Hochhaus, A. Möllmann, H. Derendorf, H. Möllmann
A selective HPLC/RIA for the determination of budesonide

163. H. Derendorf, G. Hochhaus
Pharmacodynamic aspects of drug delivery

164. H. Möllmann, M. Wagner, B. Meibohm, G. Hochhaus, J. Barth, R. Stöckmann, M. Krieg, H. Weisser, C. Falcoz, H. Derendorf
Pharmacokinetic and pharmacodynamic evaluation of fluticasone after inhaled administration

165. D. Gravenstein, A. Suri, H. Derendorf, J. Koska
Influence of plasma expansion on plasma protein binding of ketorolac

166. H. Derendorf, G. Hochhaus, B. Meibohm, H. Möllmann, J. Barth
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids

167. E. Liang, H. Derendorf
Pitfalls in pharmacokinetic multi-compartmental analysis
168. S.A. Lottenberg, D. Gianella-Neto, H. Derendorf, M. Rocha, A. Bosco, S.V. Carvalho, A.E. Moretti, A.C. Lerario, B.L. Wajchenberg
Effect of fat distribution on the pharmacokinetics of cortisol in obesity

The clinical pharmacology of fluticasone propionate

170. Hämmerlein, H. Derendorf, D. Lowenthal
Pharmacokinetic and pharmacodynamic changes in the elderly - clinical implications

171. H. Sourgens, R. Hoerr, A. Biber, H. Steinbrede, H. Derendorf
KA 672-HCl, a neuronal activator against dementia: Tolerability, safety and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers

Determination of free interstitial concentrations of piperacillin-tazobactam combinations by microdialysis

173. H. Möllmann, M. Wagner, J. Barth, H. Derendorf, M. Schulz
Broncholytics/Antiasthmatics - Fluticasone

174. S. Modric, A.I. Webb, H. Derendorf

175. M. Wagner, R. Stöckmann, A.C. Möllmann, G. Hochhaus, H. Derendorf, J. Barth, H. Möllmann
Fluticasone propionate: First long-acting inhaled corticosteroid
176. A. de la Peña, H. Derendorf
Pharmacokinetic properties of beta-lactamase inhibitors

177. B. Meibohm, G. Hochhaus, H. Möllmann, J. Barth, M. Wagner, M. Krieg, R. Stöckmann, H. Derendorf
A PK/PD approach to predict the cumulative cortisol suppression of inhaled corticosteroids

178. E.U. Graefe, H. Derendorf, M. Veit
Pharmacokinetics and bioavailability of the flavonol quercetin in humans

179. I. Beierle, B. Meibohm, H. Derendorf
Gender differences in pharmacokinetics and pharmacodynamics

Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans

Mechanism based PK/PD -model for the lymphocytopenia induced by endogenous and exogenous corticosteroids

182. H. Derendorf, B. Meibohm
Modeling of pharmacokinetic/pharmacokinetic (PK/PD) relationships: Concepts and perspectives

183. C. Rojas, N.V. Nagaraja, H. Derendorf
In vitro recovery of triamcinolone acetonide in microdialysis
Pharmacodynamic effects of an accidental triamcinolone acetonide overdose - a case study

185. M. Schwahn, N.V. Nagaraja, H. Derendorf
Population pharmacokinetic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs
Pharm. Res. 17, 328-335 (2000).

Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers

187. A. de la Peña, A. Gräbe, H. Derendorf
Pharmacokinetics of beta-lactamase inhibitors in renal impairment (in German)

A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans

Pharmacokinetic/pharmacodynamic modeling in drug research and development

190. H. Derendorf, G. Hochhaus, S. Krishnaswami, B. Meibohm, H. Möllmann
Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism
191. S. Krishnaswami, H. Möllmann, H. Derendorf, G. Hochhaus
A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma

Population pharmacokinetics of digoxin in Korean patients

193. A. de la Peña, P. Liu, H. Derendorf
Microdialysis in peripheral tissues

194. G. Hochhaus, J. Barrett, H. Derendorf
Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century

195. S. Krishnaswami, G. Hochhaus, H. Derendorf
An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy

196. B. Meibohm, H. Derendorf
Pharmacokinetics and pharmacodynamics of biotechnological drugs (in German)

PK/PD modeling of cetrorelix, a LH-RH antagonist, after subcutaneous administration in healthy postmenopausal women

198. A. Kovar, T. Peters, N. Beier, H. Derendorf
Pharmacokinetic/pharmacodynamic evaluation of eniporide
199. G. Hochhaus, J. Barth, S. Al-Fayoumi, S. Suarez, H. Derendorf, H. Möllmann
Pharmacokinetics and pharmacodynamics of dexamethasone sodium-m-sulfobenzoate (DS) after intravenous and intramuscular administration: A comparison with dexamethasone phosphate (DP)

200. H. Derendorf, G. Hochhaus, H. Möllmann
Evaluation of pulmonary absorption using pharmacokinetic methods

Population pharmacokinetics of intramuscular quinine in children with severe malaria

Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder

Systemic bioavailability of inhaled steroids: The importance of appropriate and comparable methodology

Pharmacokinetics and bioavailability of quercetin glycosides in humans
205. A. Tromm, H. Möllmann, J. Barth, G. Hochhaus, M. Krieg, C. Bigalke, A. Möllmann, H. Derendorf
Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients

206. C. Joukhadar, H. Derendorf, M. Müller
Microdialysis – a novel tool for clinical studies of antiinfective agents

Current concepts in pharmacokinetics and their implications for clinical medicine

Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats

209. H. Derendorf, S. Krishnaswami, G. Hochhaus, H. Möllmann
Systemic disposition and effects of inhaled corticosteroids

Factors involved in the pulmonary targeting of inhaled glucocorticoids

211. B. Meibohm, H. Derendorf
Pharmacokinetic/pharmacodynamic studies in drug product development
Bioavailability and metabolism of mometasone furoate - pharmacology versus methodology

Comparative target site pharmacokinetics of immediate and modified-release formulations of cefaclor in humans

214. G. Hochhaus, S. Sahasranaman, H. Derendorf, H. Möllmann
Intranasal glucocorticoid delivery: competition between local and systemic effects

Soft cannabinoid analogues as potential anti-glaucoma agents

216. P. Liu, M. Müller, M. Grant, A. Webb, B. Obermann, H. Derendorf
Interstitial tissue concentration of cefpodoxime

217. B. Meibohm, I. Beierle, H. Derendorf
How important are gender differences in pharmacokinetics

218. P. Liu, M. Müller, H. Derendorf
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs


227. H. Sourgens, J. Schmidt, H. Derendorf
Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study

Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children

229. B. Meibohm, H. Derendorf
Pharmacokinetics and pharmacodynamics of biotechnology products (in Polish)

Inhaled corticosteroids: Past lessons and future issues

231. A.M. Persky, N.D. Eddington, H. Derendorf
A review of the effects of chronic exercise and physical fitness level on resting pharmacokinetics

232. P. Liu, H. Derendorf
Antimicrobial tissue concentrations

Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective
PK-PD modeling of the effect of cefaclor on four different bacterial strains

235. B. Meibohm, H. Derendorf
Pharmacokinetics and pharmacodynamics of biotech drugs
(2004).

236. M. Müller, A. de la Pena, H. Derendorf
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Kill curves versus MIC

Intranasal loteprednol etabonate in healthy male subjects: Pharmacokinetics and effects on endogenous cortisol

238. Q. Liu, K. Rand, H. Derendorf
Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations

239. H. Derendorf
Relevant pharmacokinetic parameters for determining efficacy and safety ininhaled corticosteroids

240. A. Graebe, E.L. Schuck, P. Lensing, L. Putcha, H. Derendorf
Physiological, pharmacokinetic and pharmacodynamic changes in space

241. M. Müller, A. de la Pena, H. Derendorf
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Distribution in tissue
242. J. Winkler, G. Hochhaus, H. Derendorf
How the lung handles drugs: Pharmacokinetics and pharmacodynamics of inhaled corticosteroids

243. V.A. Schuck, I. Rinas, H. Derendorf
In vitro microdialysis sampling of docetaxel

244. K. Kim, J.A. Johnson, H. Derendorf
Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms

Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury

246. V. Butterweck, H. Derendorf, W. Gaus, A. Nahrstedt, V. Schulz, M. Unger
Pharmacokinetic herb-drug interactions: Are preventive screenings necessary and appropriate?

247. H. Derendorf, S. Pedersen
Choosing an inhaled corticosteroid for once-daily administration in asthma
Resp. Dig. 6(2), 1-11 (2004).

Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans

249. V.A. Bhattaram, N.V. Nagaraja, T. Peters, T. Machnig, S. Kroesser, A. Kovar, H. Derendorf
Population pharmacokinetics of eniporide and its metabolite in healthy subjects and patients with acute myocardial infarction
250. S. Krishnaswami, G. Hochhaus, H. Möllmann, H. Derendorf
Interpretation of absorption rate data for fluticasone propionate obtained in compartmental pharmacokinetic modeling

Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion

252. O. Burkhardt, J. Majcher-Peszynska, K. Borner, R. Mundkowski, B. Drewelow, H. Derendorf, T. Welte
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form

Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for antiinfective drugs: An update

255. P. Liu, K.H. Rand, B. Obermann, H. Derendorf
Pharmacokinetic-pharmacodynamic modeling of antibacterial activity of cefpodoxime and cefixime in vitro kinetic models

256. P. Liu, R. Fuhrherr, A.I. Webb, B. Obermann, H. Derendorf
Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats

257. P. Liu, M. Müller, M. Grant, B. Obermann, H. Derendorf
Tissue penetration of cefpodoxime and cefixime in healthy subjects
258. W.R. Heizmann, H. Derendorf
Criteria for comparison of the combinations
piperacillin/tazobactam and piperacillin/sulbactam

259. H. Derendorf, G. Hochhaus
What is the best marker for inhaled corticosteroid
safety?

260. E.L. Schuck, M. Grant, H. Derendorf
Effect of simulated microgravity on the disposition
and tissue penetration of ciprofloxacin in healthy
volunteers

261. H. Derendorf, C.P. Van der Maelen, R.S. Brickel, T.R,
MacGregor, W. Eisert
Dipyridamole bioavailability in subjects with reduced
gastric acidity

262. R.P.E. Yanong, E.W. Curtis, V.A. Bhattaram, M.
Gopalakrishnan, N. Ketabi, N.V. Nagaraja, H. Derendorf
Pharmacokinetic studies of florfenicol in Koi Carp and
Threespot Gourami Trichogaster trichopterus after oral
and intramuscular treatment

263. E.L. Schuck, H. Derendorf
Pharmacokinetic/pharmacodynamic evaluation of anti-
infective drugs

264. M. Hübner, G. Hochhaus, H. Derendorf
Comparative pharmacology, bioavailability,
pharmacokinetics and pharmacodynamics of inhaled
glucocorticoids

265. M. Brunner, H. Derendorf, M. Müller
Microdialysis for in vivo pharmacokinetic/
pharmacodynamic characterization of anti-infective
drugs
266. H. Derendorf
Corticosteroid pharmacokinetic/pharmacodynamic parameters and their relationship to safety and efficacy
Allergy Asthma Proceed. 26, 327-335 (2005).

267. E. ElDesoky, R. Madabushi, Sel D. Amry, V.A. Bhattaram, H. Derendorf
Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense?

268. W.V. De Castro, S. Mertens-Talcott, A. Rubner, V. Butterweck, H. Derendorf
Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies

269. E. ElDesoky, H. Derendorf. U. Klotz
Variability in response to cardiovascular drugs

270. O. Burkhardt, H. Derendorf, T. Welte
Achieving eradication of MRSA colonization in patients. Therapeutic options

271. O. Burkhardt, H. Derendorf, T. Welte
New antibiotics for the treatment of MRSA infections

272. S.U. Mertens-Talcott, I. Zadezensky, W.V. De Castro, V. Butterweck, H. Derendorf
Drug interactions of grapefruit and other citrus - what have we learned?

273. R. Madabushi, B. Frank, B. Drewelow, H. Derendorf, V. Butterweck
Hyperforin in St. John’s wort drug interactions


281. O. Burkhardt, M. Brunner, S. Schmidt, M. Grant, Y. Tang, H. Derendorf
Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by microdialysis

282. U. Theuretzbacher, F. Ihle, H. Derendorf
Pharmacokinetic/pharmacodynamic profile of voriconazole

Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments

284. V.A. Bhattaram, R. Madabushi, H. Derendorf
Role of Food and Drug Administration in drug development

285. V. Butterweck, H. Derendorf
Pharmacokinetics of botanical products

Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum L.) polyphenols after ingestion of a standardized extract in healthy human volunteers

The influence of formulation on the dissolution profile of diclofenac sodium tablets
288. O. Burkhardt, H. Derendorf, D. Jäger, V. Kumar, R. Madabushi, K. Rohl, J. Barth
Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis

289. E.O. Meltzer, H. Derendorf
The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide

290. H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, W. Wurst
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma

Grapefruit-Drug Interactions: Can Interactions with drugs be avoided?

292. V. Kumar, S. Mostafa, M.W. Kayo, E.P. Goldberg, H. Derendorf
HPLC Determination of dexamethasone in human plasma and its application to an in vitro release study from endovascular stents
Pharmazie 61, 908-911 (2006).

293. J.A. Manthey, K Myung, S. Mertens-Talcott, H. Derendorf, V. Butterweck, W.W. Widmer
The isolation of minor-occurring furanocoumarins in grapefruit and analysis of their inhibition of CYP3A4 and P-glycoprotein transport of talinolol from Caco-2 cells

294. O. Burkhardt, V. Kumar, D. Katterwe, J. Majcher-Peszynska, B. Drewelow, H. Derendorf, T. Welte
Erta:penem in critically ill patients with early-onset ventilator-associated pneumonia: Pharmacokinetics with special consideration on the free drug concentration
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains

Biowaiver monographs for immediate release solid oral dosage forms: Prednisolone

297. O. Burkhardt, H. Derendorf, T. Welte
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice

298. H. Derendorf
Clinical trials and dipyridamole formulation selection

299. J. Xu, J. Winkler, H. Derendorf
A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma


AAPS-FDA workshop white paper: Microdialysis principles, application and regulatory perspectives
302. H. Derendorf
Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide

303. S. Schmidt, E. Schuck, V. Kumar, O. Burkhardt, H. Derendorf
Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentrations vs. kill curves

304. S.U. Mertens-Talcott, W.V. De Castro, J.A. Manthey, H. Derendorf, V. Butterweck
Polymethoxylated flavones and other phenolic derivates from Citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells

Biowaiver monographs for immediate release solid oral dosage forms: prednisone

Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit P-glycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells

307. Y. Li, H. Nguyen, H. Derendorf, S. Cheng, C.J. Clancy
Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography

308. M. Lobmeyer, S. Schmidt, H. Derendorf
Pharmacogenetics and personalized medicine
309. H. Derendorf, K.S. Estes
The significance of optimized formulation for dipyridamole in stroke risk reduction
European Neurological Disease 2007 (II), 21-23 (2007).

310. O. Burkhardt, H. Derendorf
Grundlage der Pharmakotherapie beim kritisch Kranken

A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro

Tissue concentrations: Do we ever learn?

Duffy antigen modifies the chemokine response in human endotoxemia

314. S. Schmidt, R. Banks, V. Kumar, K.H. Rand, H. Derendorf
Clinical microdialysis in skin and soft tissues: an update.

315. B. Meibohm, H. Derendorf
Pharmacokinetics and pharmacodynamics of biotech drugs

316. J. Xu, J. Winkler, S.N. Sabarinath, H. Derendorf
Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone
317. C. Scheerans, H. Derendorf, C. Kloft  
Proposal for a standardized identification of the mono-exponential terminal phase for orally administered drugs  

318. V. Butterweck, H. Derendorf  
Potential of pharmacokinetic profiling for detecting herbal interactions with drugs  

PK/PD: new insights for antibacterial and antiviral applications  

320. K. Blake, R. Madabushi, H. Derendorf, J. Lima  
Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma  

Effect of grapefruit juice, naringin, naringenin, and bergamottin on the intestinal carrier-mediated transport of talinolol in rats  

322. H. Derendorf, E.O. Meltzer  
molecular and clinical pharmacology of intranasal corticosteroids: Clinical and therapeutic implications  
Allergy 63, 1292-1300(2008).

323. H. Badrane, M.H. Nguyen, S. Cheng, V. Kumar, H. Derendorf, K.A. Iczkowski, C.J. Clancy  
The Candida albicans phosphatase Inp51p interacts with the EH domain protein Irs4p, regulates phosphatidylinositol-4,5-bisphosphate levels and influences hyphal formation, the cell integrity pathway and virulence  
Microbiology 154, 3296-3308 (2008).
324. S. Schmidt, K. Röck, M. Sahre, O. Burkhardt, M. Brunner, M.T. Lobmeyer, H. Derendorf
Effect of protein binding on the pharmacological activity of highly bound antibiotics

Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers

326. J. Liu, H. Pan, M.S. Gold, H. Derendorf, A.W. Bruijnzeel
Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats

327. S. Sarawek, H. Derendorf, V. Butterweck
Pharmacokinetics of luteolin and metabolites in rats
Natural Product Communications 3, 2029-2036 (2008).

328. E.S. ElDesoky, V. Kumar, M.S. Alorainy, M.M. Hamdi, H. Derendorf
Estimation of lithium clearance from routine clinical data in Egyptian bipolar patients. A population pharmacokinetic approach.

329. J. Xu, S.N. Sabarinath, H. Derendorf
Cortisol suppression as a surrogate marker for inhaled corticosteroid-induced growth retardation in children

330. O.G. Ghobrial, H. Derendorf, J.D. Hillman
Pharmacodynamic activity of the lantibiotic MU1140

331. O.G. Ghobrial, H. Derendorf, J.D. Hillman
Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma
332. A. Barbour, S. Schmidt, K.H. Rand, H. Derendorf
Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)

333. A. Barbour, S. Schmidt, W.R. Rout, K. Ben-David, O. Burkhardt, H. Derendorf
Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery

Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis

335. V. Butterweck, I. Zdrojewski, C. Galloway, R. Freye, H. Derendorf
Toxicological and Pharmacokinetic Evaluation of Concomitant Intake of Grapefruit Juice and Simvastatin in Rats after Repeated Treatment over 28 Days

Pharmacokinetic/pharmacodynamic modelling and in vitro simulation of dynamic voriconazole-Candida interactions

337. K. Woelkart, R.F. Freye, H. Derendorf, R. Bauer, V. Butterweck
Pharmacokinetics and Tissue Distribution of Dodeca-2E,4E,8E,10E/Z-tetraenoic Acid Isobutylamides after Oral Administration in Rats

338. A. Barbour, S. Schmidt, B. Ma, L. Schiefelbein, K.H. Rand, O. Burkhardt, H. Derendorf
Clinical pharmacokinetics and pharmacodynamics of tigecycline
339. S. Schmidt, S. N. Sabarinath, A. Barbour, D. Abbanat, P. Manitpisitkul, S. Sha, H. Derendorf
Pharmacokinetic/pharmacodynamic modeling of the in vitro activity of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus

Influence of the duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo

341. D. Gonzalez, H. Derendorf
Ciclosenide in the management of asthma
Clinical Medicine: Therapeutics 1, 1437-1449 (2009).

342. O. Burkhardt, V. Kumar, S. Schmidt, J.T. Kielstein, T. Welte, H. Derendorf
Underdosing of ertapenem in critically ill patients with pneumonia confirmed by Monte Carlo simulations.

Preadolescent tobacco smoke exposure leads to acute nicotine dependence but does not affect the rewarding effects of nicotine or nicotine withdrawal in adulthood in rats.
Pharmacol Biochem Behav. 95, 401-409 (2010).

344. A. Barbour, F. Scaglione, H. Derendorf
Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices.

345. S. Schmidt, D. Gonzalez, H. Derendorf
Significance of protein binding in pharmacokinetics and pharmacodynamics.

346. J. Xu J, R. Nave, G. Lahu, E. Derom, H. Derendorf
Population Pharmacokinetics and Pharmacodynamics of
Inhaled Ciclesonide and Fluticasone Propionate in Patients With Persistent Asthma.

347. O. Ghobrial, H. Derendorf, J.D.Hillman
Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140.

348. J. Gloede, C. Scheerans, H. Derendorf, C. Kloft
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.

349. B. Wu, H. Derendorf
Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure

Thromboelastographic and Pharmacokinetic Profiles of Micro- and Macro-emulsions of Propofol in Swine

Pharmacokinetic/pharmacodynamic profile of posaconazole

352. S.N. Sabarinath, R.P. Singh, H. Derendorf
PK-PD approaches – Antibiotic drug development

Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke

354. A. Barbour, H. Derendorf
Resistance and the management of complicated skin and
Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: Application to a pharmacokinetic study

Pharmacometrics as a discipline is entering its ‘industrialization’ phase: standards, automation, knowledge sharing, and training are critical for future success

357. J. Liu, H. Derendorf
Clinical pharmacology of addicting drugs

358. O. Ghobrial, H. Derendorf, J. Hillman
Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140

359. R. Shi, H. Derendorf
Pediatric dosing and body size in biotherapeutics
Pharmaceutics 2, 389-418 (2010).

Pharmacokinetics and Pharmacodynamics
In ‘Guidelines for the calculated parenteral initial therapy of bacterial infections in adults’ by K.F. Bodmann, B. Grabein and the PEG Expert Committee

361. K.S. Estes, H. Derendorf
Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
Tobacco smoke exposure induces nicotine dependence in rats
Psychopharmacol. 208, 143-58 (2010).

363. V. Kumar, R. Madabushi, M.B.B. Lucchesi, H. Derendorf
Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs

364. E. Potocka, R.A. Baughman, H. Derendorf
Population pharmacokinetic model of human insulin following different routes of administration

PA-824 exhibits time-dependent activity in a murine model of tuberculosis

366. R. Shi, H. Derendorf
Theoretical models for dermatokinetics of therapeutic agents

367. R. P. Singh, H. Derendorf, E. A. Ross
Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis

368. S.N. Sabarinath, B. Wu, C.A. Peloquin, H. Derendorf
Pharmacometrics in dose finding or dose optimization of anti-retroviral and anti-tubercular drugs

369. B.M. Wu, S.N. Sabarinath, K. Rand, J. Johnson, H. Derendorf
Suppression of ciprofloxacin-induced resistant Pseudomonas aeruginosa in a dynamic kill curve system
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily

HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats

Protein binding: Do we ever learn?

Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report

The effect of critical illness on drug distribution

375. A.W. Bruijnzeel, G. Rodrick, R.P. Singh, H. Derendorf, R.M. Bauzo
Repeated pre-exposure to tobacco smoke potentiates subsequent locomotor responses to nicotine and tobacco smoke but not amphetamine in adult rats

Absolute/relative bioavailability and metabolism of
dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (tetraenes) after intravenous and oral single doses to rats

377. K. Ardjomand-Wölkart, M. Kollroser, L. Li, H. Derendorf, V. Butterweck, R. Bauer
Development and validation of a LC-MS/MS method based on a new 96-well hybrid-SPE-precipitation technique for quantification of CYP450 substrates/metabolites in rat plasma

Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment

379. M. Alter, P. Doering, H. Derendorf
Medication Therapy Monitoring – Model for Germany?

380. M. Sahre, R. Naik, H. Derendorf
Clinical microdialysis in skin and soft tissues

381. E.S. El Desoky, S.N. Sabarinath, M.M. Hamdi, M. Bewernitz, H. Derendorf
Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients

382. A. Barbour, H. Derendorf
Applications of pharmacokinetic/pharmacodynamics models for the development of antimicrobial agents

Pharmacokinetics of valerenic acid in rats after
intravenous and oral administration

384. M. Bewernitz, H. Derendorf
Electroencephalogram-based pharmacodynamics measures: a review

The concentration-dependent binding of linagliptin (BI 1356) and its implication on efficacy and safety

Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray

387. M. Zeitlinger, S. Marchand, W. Couet, A. Barth, H. Derendorf
Microdialysis in antibiotic research

388. K. Chooluck, R.P. Singh, K. Sathirakul, H. Derendorf
Dermal pharmacokinetics of terpinen-4-ol following topical administration of Zingiber cassumunar (plai) oil

389. C. Lebert, H. Derendorf
Therapeutic drug monitoring of vancomycin in adults – retrospective analysis of plasma level data of 1122 patients

Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers
391. H. Derendorf  
Model-based drug approval – the rubber hits the road  

392. V. Butterweck, H. Derendorf  
Herb-drug interactions  

393. T.E. Morey, S. Wasdo, J. Wishin, B. Quinn, A. van der Straten, M. Booth, D. Gonzalez, H. Derendorf, R.J. Melker, D.M. Dennis  
Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels  

394. K. Chooluck, R.P. Singh, K. Sathirakul, H. Derendorf  
Plasma and dermal pharmacokinetics of terpinen-4-ol in rats following intravenous administration  
Pharmazie 68, 135-140 (2013).

Influence of CYP3A5 6986A>G and ABCB1 3435C>T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients  

396. H. Mückter, H. Derendorf, B. Fichtl  
Toxicokinetics  

397. M. Ibarra, M. Vazquez, P. Fagiolino, H. Derendorf  
Sex related differences on valpoic acid pharmacokinetics after oral single dose  

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study  
Oral adherence monitoring using a breath test to supplement highly active antiretroviral therapy
AIDS Behav. 17, 298-306 (2013).

400. H. Derendorf, K. Rübsamen, L. Clarke, A. Schäffler, J.R. Kirwan
Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis

A novel breath test to directly measure use of vaginal gel and condoms
AIDS Behav. 17, 2211-2221 (2013).

402. D.J. Greenblatt, H. Derendorf
Grapefruit–medication interactions
CMAJ 185, 507 (2013).

403. D. Gonzalez, S. Schmidt, H. Derendorf
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents

404. J. Heuberger, S. Schmidt, H. Derendorf
When is protein binding important?
J. Pharm. Sci. 102, 3458-3467 (2013).

405. L. Li, A.R. Han, A.D. Kinghorn, R.F. Frye, H. Derendorf, V. Butterweck
Pharmacokinetic properties of pure xanthones in comparison to a mangosteen fruit extract in rats

Electroencephalogram effects of armodafinil: Comparison with behavioral alertness
407. E.S. El Desoky, M.H. Ghazal, R.P. Singh, O.N. Abdelhamid, H. Derendorf
Population pharmacokinetics of methotrexate in Egyptian children with lymphoblastic leukemia
Pharmacology & Pharmacy 4, 139-145 (2013).

408. S.K.B. Sy, J. Heuberger, S. Shilbayeh, D.J. Conrado, H. Derendorf
A Markov Chain Model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation

409. S.K.B. Sy, S. Innes, H. Derendorf, M.F. Cotton, B. Rosenkranz
Estimation of intracellular concentration of stavudine-triphosphate in HIV-infected children given the reduced dose of 0.5 mg/kg twice daily

410. B. Wu, S.K. B. Sy, H. Derendorf
Principles of Applied Pharmacokinetic-pharmacodynamic modeling

411. J. Michael, A. Barth, C. Kloft, H. Derendorf
Pharmacodynamic in-vitro models to determine the effect of antibiotics
Series Clinical Pharmacy POP (Patient-oriented Pharmacy, in German)

1. M. Alter, I. Waltering, O. Rose, H. Derendorf
   MTM für Arzt und Patient

2. O. Rose, H. Derendorf
   Ein Patient mit Hyperlipidamie

3. M. Zieglermeier, H. Derendorf, R. Hermann
   Eine Schmerzpatientin
   Deutsche Apotheker Zeitung 152, 2478-2486 (2012).

4. A.N. Förster, H. Derendorf, R. Hermann
   Eine Hypertonie-Patientin
   Deutsche Apotheker Zeitung 152, 3088-3095 (2012).

5. M. Zieglermeier, H. Derendorf, R. Hermann
   Eine Parkinson-Patientin mit Sturzneigung
   Deutsche Apotheker Zeitung 152, 3570-3575 (2012).

6. A.N. Förster, R. Hermann, H. Derendorf
   Ein junger Asthmapatient
   Deutsche Apotheker Zeitung 152, 3992-4000 (2012).

7. O. Rose, D. Hage, H. Derendorf
   Eine depressive Patientin

8. A.N. Förster, H. Derendorf, R. Hermann
   Ein jugenderlicher Diabetiker
   Deutsche Apotheker Zeitung 152, 4980-4988 (2012).

9. O. Rose, T. Liebig, D. Maintz, H. Derendorf
   Ein Schlaganfall-Patient
   Deutsche Apotheker Zeitung 152, 5646-5655 (2012).

10. I. Waltering, J. Rech, H. Derendorf
    Eine junge Rheumapatientin
    Deutsche Apotheker Zeitung 152, 6092-6103 (2012).

11. M. Weißenborn, E. Schmitz, M. Kissel, H. Derendorf
    Körperkonzentrationen - Wichtige Grundlagen der
    Pharmakokinetik
12. M. Dircks, F. Fuchs, K. Leuner, F. Dörje, H. Derendorf
Ein Patient mit COPD

13. E. Schmitz, M. Weißenborn, M. Kissel, H. Derendorf
Der Weg durch den Körper – Resorption, Verteilung, Abbau
und Ausscheidung von Arzneistoffen

14. M. Hahn, H. Derendorf, S. Roll
Ein Patient mit bipolarer Störung

15. M. Weissenborn, E. Schmitz, M. Kissel, H. Derendorf
Drug-Level-Monitoring – Voraussetzung für die optimale
Dosierung bestimmter Arzneistoffe

16. G. Baumgärtner, M. Ziegelmeier, R. Hermann, H.
Derendorf
Eine Patientin mit Juckreiz und Ödemen

17. M. Weißenborn, E. Schmitz, M. Kissel, H. Derendorf
Gewicht, Alter, Genom – Individuelle Einflussfaktoren auf
die Pharmakokinetik

18. I. Richling, R. Hermann, H. Derendorf
Eine Patientin mit Verhütungswunsch

19. O. Rose, H. Omran, A. Dübbers, H. Derendorf
Ein Patient mit cystischer Fibrose

20. I. Waltering, T. Fey, R. Hermann, H. Derendorf
Ein Alzheimer-Patient

21. O. Rose, C. Fechtrup, H. Derendorf
Ein Patient mit Herzinsuffizienz
22. N. Förster, R. Hermann, H. Derendorf
Eine Patientin mit Herzrhythmusstörungen

23. N. Förster, R. Hermann, H. Derendorf
Eine Patientin mit Epilepsie

24. H. Derendorf, C. Kloft, U. Jaehde
Patientenorientierte Pharmazie – Gedanken zum Leitbild und
zur Ausbildung des Apothekers

25. O. Rose, D. Maintz, H. Derendorf
Eine Patientin mit fortgeschrittenem Parkinson-Syndrom